FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2797222819> ?p ?o ?g. }

• W2797222819 abstract "Background: The pangenotypic direct-acting antivirals (DAAs) glecaprevir and pibrentasvir, comprisethe interteron (IFN)- and ribavirin (RBV)-free regimen G/P. In seven phase 2/3 clinical lrials, G/Pachieved SVR12 rates of 92-100% across all six major HCV genotypes (GTs). Here we present anintegrated analysis from these studies on lhe efficacy of 8 and 12 weeks of G/P treatment in noncirrholicpatienls with GT1-6 infection. Methods: Data were pooled from the phase 2 SURVEYOR-I and-11, and phase 3 EXPEDITION-4 and ENDURANCE 1 ,2,3 and 4 sludies. Patients with chronic HCV GTt,2,3,4,5 or 6 infection without cirrhosis received G/P without RBV for either 8 or 12 weeks. Patientswere either treatment-naive or treatmenl-experienced with IFN-based or sofosbuvir (SOF)-basedregimens. Patients experienced wilh a DAA other than SOF were excluded. Efficacy was evaluated asthe rate of sustained virologic response (HCV RNA <lower limit of quantification) 12 weeks after lheend of treatment (SVR12). Safety was assessed in all patients. Results: In total, 1981 patients withoutcirrhosis were enrolled and 1975 received study drug. Select baseline characteristics are shown inTable 1. SVR12 rates by treatmenl duration and genotype, excluding 22 patients that were treated fort6 weeks, are shown in Figure 1. In lhe intent-to-treat population (ITT), 191111953 (98%) patientsachieved SVR12, with similar rales of 97% and 98% in patients lreated for 8 and 12 weeks,respectively. Across all genotypes, lhere were 4 breakthroughs (0.2%), 14 relapses (0.7%) and 11discontinualions (0.6%). G/P was well-tolerated; discontinualions due to adverse events, DAA-relaledserious adverse events and grade 3 or higher laboratory abnormalities were rare.Conclusions: The GIP regimen yielded high SVR12rates across all genotypes, regardless of priortreatment experience or treatment duration. The resultsfrom lhis integrated analysis suggest that the G/Pregimen could provide an effective 8-week IFN- andRBV-Iree treatment option for patients with HCV GT1-6infection without cirrhosis." @default.
• W2797222819 created "2018-04-24" @default.
• W2797222819 creator A5002981963 @default.
• W2797222819 creator A5010288279 @default.
• W2797222819 creator A5013628571 @default.
• W2797222819 creator A5037496721 @default.
• W2797222819 creator A5041215107 @default.
• W2797222819 creator A5047871839 @default.
• W2797222819 creator A5053190425 @default.
• W2797222819 creator A5054725734 @default.
• W2797222819 creator A5058099818 @default.
• W2797222819 creator A5058318375 @default.
• W2797222819 creator A5061315889 @default.
• W2797222819 creator A5066916785 @default.
• W2797222819 creator A5068216552 @default.
• W2797222819 creator A5071679284 @default.
• W2797222819 creator A5072868768 @default.
• W2797222819 creator A5076282431 @default.
• W2797222819 creator A5076698811 @default.
• W2797222819 creator A5080242128 @default.
• W2797222819 date "2017-09-14" @default.
• W2797222819 modified "2023-10-17" @default.
• W2797222819 title "High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis" @default.
• W2797222819 hasPublicationYear "2017" @default.
• W2797222819 type Work @default.
• W2797222819 sameAs 2797222819 @default.
• W2797222819 citedByCount "0" @default.
• W2797222819 crossrefType "journal-article" @default.
• W2797222819 hasAuthorship W2797222819A5002981963 @default.
• W2797222819 hasAuthorship W2797222819A5010288279 @default.
• W2797222819 hasAuthorship W2797222819A5013628571 @default.
• W2797222819 hasAuthorship W2797222819A5037496721 @default.
• W2797222819 hasAuthorship W2797222819A5041215107 @default.
• W2797222819 hasAuthorship W2797222819A5047871839 @default.
• W2797222819 hasAuthorship W2797222819A5053190425 @default.
• W2797222819 hasAuthorship W2797222819A5054725734 @default.
• W2797222819 hasAuthorship W2797222819A5058099818 @default.
• W2797222819 hasAuthorship W2797222819A5058318375 @default.
• W2797222819 hasAuthorship W2797222819A5061315889 @default.
• W2797222819 hasAuthorship W2797222819A5066916785 @default.
• W2797222819 hasAuthorship W2797222819A5068216552 @default.
• W2797222819 hasAuthorship W2797222819A5071679284 @default.
• W2797222819 hasAuthorship W2797222819A5072868768 @default.
• W2797222819 hasAuthorship W2797222819A5076282431 @default.
• W2797222819 hasAuthorship W2797222819A5076698811 @default.
• W2797222819 hasAuthorship W2797222819A5080242128 @default.
• W2797222819 hasConcept C104317684 @default.
• W2797222819 hasConcept C126322002 @default.
• W2797222819 hasConcept C135763542 @default.
• W2797222819 hasConcept C141071460 @default.
• W2797222819 hasConcept C197934379 @default.
• W2797222819 hasConcept C203014093 @default.
• W2797222819 hasConcept C2522874641 @default.
• W2797222819 hasConcept C2776408679 @default.
• W2797222819 hasConcept C2777214474 @default.
• W2797222819 hasConcept C2778390639 @default.
• W2797222819 hasConcept C2780040827 @default.
• W2797222819 hasConcept C2781413609 @default.
• W2797222819 hasConcept C2908647359 @default.
• W2797222819 hasConcept C55493867 @default.
• W2797222819 hasConcept C71924100 @default.
• W2797222819 hasConcept C86803240 @default.
• W2797222819 hasConcept C90924648 @default.
• W2797222819 hasConcept C99454951 @default.
• W2797222819 hasConceptScore W2797222819C104317684 @default.
• W2797222819 hasConceptScore W2797222819C126322002 @default.
• W2797222819 hasConceptScore W2797222819C135763542 @default.
• W2797222819 hasConceptScore W2797222819C141071460 @default.
• W2797222819 hasConceptScore W2797222819C197934379 @default.
• W2797222819 hasConceptScore W2797222819C203014093 @default.
• W2797222819 hasConceptScore W2797222819C2522874641 @default.
• W2797222819 hasConceptScore W2797222819C2776408679 @default.
• W2797222819 hasConceptScore W2797222819C2777214474 @default.
• W2797222819 hasConceptScore W2797222819C2778390639 @default.
• W2797222819 hasConceptScore W2797222819C2780040827 @default.
• W2797222819 hasConceptScore W2797222819C2781413609 @default.
• W2797222819 hasConceptScore W2797222819C2908647359 @default.
• W2797222819 hasConceptScore W2797222819C55493867 @default.
• W2797222819 hasConceptScore W2797222819C71924100 @default.
• W2797222819 hasConceptScore W2797222819C86803240 @default.
• W2797222819 hasConceptScore W2797222819C90924648 @default.
• W2797222819 hasConceptScore W2797222819C99454951 @default.
• W2797222819 hasLocation W27972228191 @default.
• W2797222819 hasOpenAccess W2797222819 @default.
• W2797222819 hasPrimaryLocation W27972228191 @default.
• W2797222819 hasRelatedWork W1891692245 @default.
• W2797222819 hasRelatedWork W2006280021 @default.
• W2797222819 hasRelatedWork W2068475242 @default.
• W2797222819 hasRelatedWork W2156761250 @default.
• W2797222819 hasRelatedWork W2170609967 @default.
• W2797222819 hasRelatedWork W2319689786 @default.
• W2797222819 hasRelatedWork W2502822043 @default.
• W2797222819 hasRelatedWork W2738705340 @default.
• W2797222819 hasRelatedWork W2751450406 @default.
• W2797222819 hasRelatedWork W2768486652 @default.
• W2797222819 hasRelatedWork W2784719900 @default.
• W2797222819 hasRelatedWork W2792190643 @default.
• W2797222819 hasRelatedWork W2885623036 @default.
• W2797222819 hasRelatedWork W2900625000 @default.
• W2797222819 hasRelatedWork W2966397374 @default.

• next